FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

By
Kathryn Wighton
March 27, 2026
2 min

Conexiant

Share

The FDA has revised the prescribing information for Neffy, an epinephrine nasal spray, eliminating the minimum age requirement for its 1 mg dose. This expansion allows younger pediatric patients weighing at least 33 pounds to access this life-saving treatment for type I allergic reactions and anaphylaxis. Approximately 25% of patients who need epinephrine fall in the 33 to less than 66-pound range, which includes younger children. The updated guidelines also provide instructions on storage and handling, emphasizing the importance of carrying two devices and seeking emergency care after use.